GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (MEX:BIIB) » Definitions » E10

Biogen (MEX:BIIB) E10 : MXN344.25 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Biogen E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Biogen's adjusted earnings per share data for the three months ended in Mar. 2024 was MXN44.810. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is MXN344.25 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biogen's average E10 Growth Rate was 2.20% per year. During the past 3 years, the average E10 Growth Rate was 8.60% per year. During the past 5 years, the average E10 Growth Rate was 13.30% per year. During the past 10 years, the average E10 Growth Rate was 20.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Biogen was 186.40% per year. The lowest was -64.80% per year. And the median was 43.20% per year.

As of today (2024-07-23), Biogen's current stock price is MXN4026.63. Biogen's E10 for the quarter that ended in Mar. 2024 was MXN344.25. Biogen's Shiller PE Ratio of today is 11.70.

During the past 13 years, the highest Shiller PE Ratio of Biogen was 110.75. The lowest was 9.23. And the median was 28.55.


Biogen E10 Historical Data

The historical data trend for Biogen's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen E10 Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 271.97 328.66 360.15 394.85 353.12

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 369.90 354.47 362.03 353.12 344.25

Competitive Comparison of Biogen's E10

For the Drug Manufacturers - General subindustry, Biogen's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Biogen's Shiller PE Ratio falls into.



Biogen E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biogen's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=44.81/131.7762*131.7762
=44.810

Current CPI (Mar. 2024) = 131.7762.

Biogen Quarterly Data

per share eps CPI Adj_EPS
201406 39.038 100.560 51.157
201409 48.606 100.428 63.778
201412 55.165 99.070 73.377
201503 53.205 99.621 70.378
201506 61.662 100.684 80.704
201509 70.127 100.392 92.050
201512 64.825 99.792 85.602
201603 76.258 100.470 100.019
201606 88.584 101.688 114.795
201609 91.070 101.861 117.816
201612 61.645 101.863 79.748
201703 65.148 102.862 83.461
201706 73.569 103.349 93.805
201709 105.077 104.136 132.967
201712 -27.692 104.011 -35.084
201803 100.649 105.290 125.968
201806 82.135 106.317 101.804
201809 133.741 106.507 165.472
201812 92.874 105.998 115.461
201903 138.696 107.251 170.413
201906 150.790 108.070 183.868
201909 165.635 108.329 201.485
201912 152.389 108.420 185.217
202003 189.460 108.902 229.256
202006 221.357 108.767 268.183
202009 98.526 109.815 118.230
202012 46.149 109.897 55.337
202103 54.986 111.754 64.837
202106 59.519 114.631 68.421
202109 45.648 115.734 51.975
202112 51.285 117.630 57.453
202203 41.017 121.301 44.559
202206 145.654 125.017 153.529
202209 157.702 125.227 165.950
202212 73.890 125.222 77.758
202303 48.127 127.348 49.801
202306 69.776 128.729 71.428
202309 -8.187 129.860 -8.308
202312 29.026 129.419 29.555
202403 44.810 131.776 44.810

Add all the adjusted EPS together and divide 10 will get our e10.


Biogen  (MEX:BIIB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Biogen's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=4026.63/344.25
=11.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Biogen was 110.75. The lowest was 9.23. And the median was 28.55.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Biogen E10 Related Terms

Thank you for viewing the detailed overview of Biogen's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (MEX:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (MEX:BIIB) Headlines

From GuruFocus

Biogen Inc at Cowen Health Care Conference Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc Analyst Q&A Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024